USA flag logo/image

An Official Website of the United States Government

Further Analysis of a VLS Modified IL-2 Receptor Targeted Toxin

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
88722
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
AI076205
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ANJIN GROUP, INC.
10 CHILHOWIE CT. COCKEYSVILLE, MD 21030 2202
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: Further Analysis of a VLS Modified IL-2 Receptor Targeted Toxin
Agency: HHS
Contract: 1R43AI076205-01A1
Award Amount: $147,459.00
 

Abstract:

DESCRIPTION (provided by applicant): The project seeks to further the development of a series of diphtheria toxin mutants which, when employed in the construction of protein fusion toxins, display reduced induction of leakage through vascular endothelial c ell monolayers. The goals of this Phase I proposal are to evaluate two, in vivo models of vascular leakage, selecting one model for further in vivo analysis of diphtheria toxin mutants generated by AGI. Successful completion of these studies will result in the determination of modified diphtheria toxin toxophores suitable for protein fusion toxin development and testing in disease-specific, in vivo models. Vascular leakage in humans is a common side effect of fusion toxin therapy and may be inhibiting the d evelopment of this class of therapeutic agent. Advances in reduction of vascular leakage could enhance the therapeutic index of these drugs and make them available to a wider population of patients. Currently there is only one FDA approved drug in this cla ss, ONTAK, which is used to treat persistent or recurrent cutaneous T-cell lymphoma. Sales of this drug range between 30 and 40M annually. PUBLIC HEALTH RELEVANCE: This project seeks to develop modified diphtheria toxin interleukin-2 molecules with reduc ed side effect profiles. In excess of 30% of all patients that currently receive DAB389IL-2, or ONTAK(r), experience vascular leak syndrome. The molecules being developed and tested in these studies will potentially provide a path for the development of th e next generation of ONTAK(r) that may be more appropriate for a wider patient population afflicted with a broader range of diseases.

Principal Investigator:

Business Contact:

Small Business Information at Submission:

ANJIN GROUP, INC.
10 CHILHOWIE CT. COCKEYSVILLE, MD 21030

EIN/Tax ID: 020669751
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No